
|Videos|October 6, 2017
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
Author(s)John Wagstaff, MD
John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Advertisement
John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. These trials showed response rates in the second-line setting of 15% to 25%.
Patients with melanoma who respond to immunotherapy see years of survival benefit; however, longer follow-up is needed to determine if this is the case in bladder cancer, states Wagstaff.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5


































